Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Brady L SteinRonald Hoffman

Abstract

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm that is associated with a substantial symptom burden, thrombohemorrhagic complications, and impaired survival. A decade after the seminal discovery of an activating mutation in the tyrosine kinase JAK2 in nearly all patients with PV, new treatment options are finally beginning to emerge, necessitating a critical reappraisal of the underlying pathogenesis and therapeutic modalities available for PV. Herein, we comprehensively review clinical aspects of PV including diagnostic considerations, natural history, and risk factors for thrombosis. We summarize recent studies delineating the genetic basis of PV, including their implications for evolution to myelofibrosis and secondary acute myeloid leukemia. We assess the quality of evidence to support the use of currently available therapies, including aspirin, phlebotomy, hydroxyurea, and interferon. We analyze recent studies evaluating the safety and efficacy of JAK inhibitors, such as ruxolitinib, and evaluate their role in the context of other available therapies for PV. This review provides a framework for practicing hematologists and oncologists to make rational treatment decisions for patients with PV.

References

Feb 19, 1981·The New England Journal of Medicine·P D BerkL R Wasserman
Apr 27, 1995·The New England Journal of Medicine·S CortelazzoT Barbui
Nov 10, 2001·Hematology·Thomas C. PearsonGuido Finazzi
Jan 9, 2004·The New England Journal of Medicine·Raffaele LandolfiUNKNOWN European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators
Nov 16, 2004·The American Journal of Medicine·Francesco PassamontiMario Lazzarino
Feb 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roberto MarchioliTiziano Barbui
Mar 23, 2005·Lancet·E Joanna BaxterUNKNOWN Cancer Genome Project
Apr 29, 2005·The New England Journal of Medicine·Robert KralovicsRadek C Skoda
Jul 8, 2005·The New England Journal of Medicine·Claire N HarrisonUNKNOWN United Kingdom Medical Research Council Primary Thrombocythemia 1 Study
Nov 16, 2006·Blood·Raffaele LandolfiUNKNOWN European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP)
Dec 13, 2006·British Journal of Haematology·Marcello Di NisioUNKNOWN European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) Investigators
Feb 3, 2007·The New England Journal of Medicine·Linda M ScottAnthony R Green
Jul 7, 2007·British Journal of Haematology·Naseema GangatAyalew Tefferi
Jul 13, 2007·Leukemia·A M VannucchiUNKNOWN MPD Research Consortium
Jan 2, 2008·Haematologica·Elisabetta AntonioliUNKNOWN Myeloproliferative Disorders Research Consortium (MPD-RC)
May 29, 2009·The New England Journal of Medicine·François DelhommeauOlivier A Bernard
Sep 17, 2010·The New England Journal of Medicine·Terra L LashoAyalew Tefferi
Jan 6, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tiziano BarbuiUNKNOWN European LeukemiaNet
May 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Magnus BjörkholmOla Landgren
Sep 14, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Jacques KiladjianJean-Didier Rain
Apr 25, 2012·Leukemia & Lymphoma·Maya Koren-MichowitzArnon Nagler
Jul 13, 2012·Blood Reviews·Tiziano BarbuiGuido Finazzi
Oct 17, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robyn M EmanuelRuben A Mesa

❮ Previous
Next ❯

Citations

Nov 4, 2015·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Robert Roskoski
Jul 16, 2016·Blood·V Nathan Subramaniam
Dec 27, 2016·Thrombosis Research·Wai Khoon Ho, Frank S Hong
Jun 13, 2017·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Jeffrey S ChangHui-Ju Ch'ang
Oct 17, 2017·Current Hematologic Malignancy Reports·Brady L Stein, Srdan Verstovsek
Feb 6, 2018·Annals of Hematology·Jean-Jacques KiladjianSrdan Verstovsek
Jun 1, 2017·American Society of Clinical Oncology Educational Book·Mintallah HaiderAlan F List
Dec 31, 2015·Current Opinion in Hematology·Daniel Aruch, John Mascarenhas
May 24, 2016·Journal of Clinical Immunology·Eric Allenspach, Troy R Torgerson
Dec 21, 2017·Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen·V LuberS Knop
Dec 30, 2017·Annals of Hematology·Juliana E Hidalgo LópezGuilin Tang
Aug 16, 2018·Frontiers in Oncology·Emira Bousoik, Hamidreza Montazeri Aliabadi
Jul 26, 2018·Leukemia·Yelena Z GinzburgRonald Hoffman
Dec 5, 2020·Hematology·Alison R Moliterno, Hannah Kaizer
May 30, 2021·Biomarker Research·Rory M Shallis, Nikolai A Podoltsev

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Annals of Hematology
Martin GriesshammerRuben A Mesa
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Hun Ju LeeFarhad Ravandi
Clinical Lymphoma, Myeloma & Leukemia
Lorenzo FalchiSrdan Verstovsek
© 2021 Meta ULC. All rights reserved